Adverse event development in clinical oncology trials.

[1]  Virginie Rondeau,et al.  Joint model for left‐censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000–05 trial , 2016, Biometrics.

[2]  Friedhelm Leverkus,et al.  Safety data from randomized controlled trials: applying models for recurrent events , 2016, Pharmaceutical statistics.

[3]  M. Schumacher,et al.  Analysing adverse events by time‐to‐event models: the CLEOPATRA study , 2016, Pharmaceutical statistics.

[4]  Claudia Schmoor,et al.  Statistical issues in the analysis of adverse events in time‐to‐event data , 2016, Pharmaceutical statistics.

[5]  P. Novotny,et al.  Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. , 2016, The Lancet. Oncology.

[6]  R. Bender,et al.  Biometrical issues in the analysis of adverse events within the benefit assessment of drugs , 2016, Pharmaceutical statistics.

[7]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[8]  Michael J. Green,et al.  Latent class analysis was accurate but sensitive in data simulations , 2014, Journal of clinical epidemiology.

[9]  Katherine E. Masyn,et al.  General growth mixture modeling for randomized preventive interventions. , 2001, Biostatistics.